Inclusion Criteria:

Histologically confirmed diagnosis of cancer for which standard chemotherapy will produce
a very high likelihood of oral, esophageal or gastrointestinal mucositis (e.g. high dose
chemotherapy with stem cell reconstitution in patients with multiple myeloma; concurrent
5-FU/ cisplatin and radiotherapy to the head and neck area; patients receiving
paclitaxel). Patients receiving concurrent chemotherapy/radiation therapy for lung or
gastrointestinal cancer are eligible.

If not receiving a highly mucosally toxic regimen, have had Grade 2 mucositis on the
prior cycle of chemotherapy Have no evidence of active infection in the oral cavity such
as thrush, HSV, or aphthous ulcers.

Patients must be free of known infectious stomatitis or systemic infection (culture not
required). If unclear that the patient has infectious stomatitis, cultures may be
obtained and the patient entered on study.

Must be free of Grade 3 or 4 vomiting. Have no contraindication for buccal scrapings. Not
be a frequent (>3 cups per day) tea drinker Must be able to speak English.

Exclusion Criteria:

Xerostomia Use of any investigational agent (not FDA approved) Current use of,
allopurinol, prostaglandin inhibitors, sulcralfate, vitamin E or antioxidant supplements
during the course of this study.

Patients receiving an anesthetic "cocktail" regimen or other topical anesthetics.

Patients with existing oral lesions.